Reducing Avoidable Medication-Related Harm : What Will it Take?
Consumption of quality-assured medicines is expected to maintain or improve population health. Yet in a number of situations, what is realized is lower health benefits or magnified safety-risks. Recognizing the public-health implications of safety-risks or medication-related harm, and that harm can be unavoidable and avoidable, the World Health Organization has initiated the third Global Patient Safety challenge on Medication Safety. Under the term “Medication Without Harm”, this Challenge aims to assess the scope and nature of avoidable medication-related harm, create a framework for intervention and develop national guidance and tools to support safer medication use. The global target under the Challenge is to reduce the level of severe avoidable medication-related harm by 50% over a five year period or within the next five years. Given a higher morbidity and mortality due to medication-related harm in low-income countries, this paper evaluates what needs to be done in low-income countries in order to achieve the global target. The ideal solution advocated requires that health planners in each low-income country determine what fraction of safety-risks or harm can be prevented; and the relationship between number or frequency of avoidable harm or safety-risks and the resource costs of treatment or prevention. In the absence of such information, this paper discusses a number of prevention strategies that might help; arguing that the period over which avoidable medication-related harm can be reduced by 50% will depend, at least, on whether significant continuous investments in health-system strengthening are made prior to and within that period
Year of publication: |
2020
|
---|---|
Authors: | Tetteh, Ebenezer Kwabena |
Publisher: |
[2020]: [S.l.] : SSRN |
Saved in:
freely available
Extent: | 1 Online-Ressource (30 p) |
---|---|
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments October 4, 2018 erstellt |
Other identifiers: | 10.2139/ssrn.3260474 [DOI] |
Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10012851200
Saved in favorites
Similar items by person
-
Discrete-choice modelling of patient preferences for modes of drug administration
Tetteh, Ebenezer Kwabena, (2017)
-
Manufacturing, Supply and Pricing of Pharmaceuticals : Lessons from Biologically-Derived Products
Tetteh, Ebenezer Kwabena, (2021)
-
Consolidation or Multiplicity in Supply Logistics for Health Commodities?
Tetteh, Ebenezer Kwabena, (2020)
- More ...